4 mL (Note: This volume does not allow for repeat testing.)
Gel-barrier tube or red-top tube
Serum must be separated from cells within 45 minutes of venipuncture. Send serum in a plastic transport tube.
EDTA plasma; citrated plasma; hemolysis greater than 5%
This panel is intended to aid physicians in diagnosing polycystic ovary syndrome (PCOS) by assessing biochemical hyperandrogenism and ruling out other disorders that mimic the clinical features of PCOS. This assay provides the sensitivity and specificity required for the assessment of the low testosterone levels found in women, children, adolescents, and hypogonadal men.1
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
HPLC/tandem mass spectrometry (LC/MS-MS), Electrochemiluminescent (ECLIA), Immunochemiluminometric (ICMA), 2-site electrochemiluminescenceis
PCOS is the most common endocrine disorder in reproductive-aged women affecting more than 5 million women in the United States.2 Guidelines recommend a diagnosis of PCOS if two of the three following criteria are met: androgen excess, ovulatory dysfunction, or polycystic ovaries.
Measurement of total or free testosterone should be done using liquid chromatography-mass spectrometry (LCMS) assays. Guidelines also recommend excluding thyroid disease (TSH), prolactin excess (prolactin), and nonclassical congenital adrenal hyperplasia (17-OH progesterone) before diagnosing PCOS. Additionally, women should potentially be evaluated to rule out pregnancy, hypothalamic amenorrhea (HA), primary ovarian insufficiency, androgen-secreting tumor, Cushing's syndrome and acromegaly depending on clinical presentation.3,4
Once diagnosed, assessment and management of reproductive, metabolic and psychological features is vital to patient care. Many significant comorbidities are associated with PCOS, and additional testing for monitoring is recommended. Women with PCOS experience symptoms of androgen excess associated with PCOS, and additional testing for monitoring is recommended. Women with PCOS experience symptoms of androgen excess associated with menstrual abnormalities and infertility. Chronic anovulation experienced by patients with PCOS increases their risk of developing endometrial cancer. Women with PCOS are often overweight and are likely to suffer from insulin resistance, putting them at increased risk for developing type 2 diabetes mellitus and nonalcoholic steatohepatitis (NASH).5-7 Lipid abnormalities, including decreased high-density lipoprotein cholesterol levels and elevated triglyceride levels, as well as impaired fibrinolysis, are seen in women with PCOS.6,8 Cardiovascular disease is more prevalent, and women with PCOS have a significantly increased risk for myocardial infarction.6,8
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|505550||PCOS Diagnostic Profile||500478||TSH-ICMA||uU/mL||3016-3|
|505550||PCOS Diagnostic Profile||500160||Testosterone, Total||ng/dL||2986-8|
|505550||PCOS Diagnostic Profile||500727||% Free Testosterone (Dialysis)||%||15432-8|
|505550||PCOS Diagnostic Profile||500728||Free Testosterone, Serum||pg/mL||2991-8|
|505550||PCOS Diagnostic Profile||500095||Luteinizing Hormone (LH) ECL||mIU/mL||10501-5|
|505550||PCOS Diagnostic Profile||500098||Follicle Stimulating Hormone||mIU/mL||15067-2|
|505550||PCOS Diagnostic Profile||500558||Prolactin||ng/mL||2842-3|
|505550||PCOS Diagnostic Profile||500164||17-Alpha-Hydroxyprogesterone||ng/dL||1668-3|
|505550||PCOS Diagnostic Profile||503630||DHEA-Sulfate, LCMS||ug/dL||2191-5|
|505550||PCOS Diagnostic Profile||500433||Sex Hormone Binding Globulin||nmol/L||13967-5|
|505550||PCOS Diagnostic Profile||502608||Estradiol, Serum, MS||pg/mL||35384-7|
|505550||PCOS Diagnostic Profile||500184||Anti-Mullerian Hormone (AMH)||ng/mL||38476-8|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf